OS6.2 Medulloblastoma recurrence: Improved survival with a metronomic and targeted antiangiogenesis therapy - experience in 
18 patients

ABSTRACT: Abstract

Introduction:

Patients with recurrent medulloblastoma have a poor prognosis with approximately 8% surviving more than 5 years irrespective of salvage therapy used. An evolving alternative approach to conventional chemotherapy is to target neovascularisation by interfering with tumor angiogenesis at various levels. We report on 18 patients treated with an antiangiogenic combination therapy at the Medical University of Vienna

Patients and Methods:

From 11/2006 to 10/2015, 18 patients were diagnosed with a recurrent medulloblastoma (12 first, 6 multiple recurrences). Subgroup of medulloblastoma was group 3 or 4 in 13 patients, WNT in one patient, SHH infant in one, and not known in three. Median age at primary diagnosis was 7 years (range 0.5–12) and at start of ant

SUBMITTER: Slavc I 

PROVIDER: S-EPMC5782543 | biostudies-literature | 2016 Sep

REPOSITORIES: biostudies-literature